key: cord-0958465-id8edui2
authors: Chew, Nicholas WS; Ngiam, Jinghao Nicholas; Sia, Ching-Hui
title: The Utility of CHA(2)DS(2)-VASc Scores as a Risk Assessment Tool in Low-Risk In-Hospital Patients With Coronavirus Disease 2019 Infection
date: 2020-12-04
journal: Am J Cardiol
DOI: 10.1016/j.amjcard.2020.12.005
sha: 3dfce854cb423894531d3320b375b44860e54f9d
doc_id: 958465
cord_uid: id8edui2

nan

Coronavirus disease 2019 (COVID-19) infections can have serious consequences such as cardiac manifestations, severe coagulopathy and thromboembolism (1) (2) (3) (4) . We read with interest the study by Ruocco et al. published in the American Journal of Cardiology (5) . This study, performed on an Italian cohort, showed that the CHA(2)DS(2)-VASc score could aid prognostication of mortality and a composite end-point of inpatient death or invasive ventilation across CHA(2)DS(2)-VASc tertiles in COVID-19 patients.

In Singapore, there has been a demographic shift in COVID-19 cases initially involving at-risk elderly population in the community, and transitioning to cluster outbreaks in densely-populated foreign worker dormitories (6) . Active case finding of dormitory residents resulted in a surge of swab-positive COVID-19 patients who were either asymptomatic or mildly symptomatic. They were admitted to hospital for risk assessment prior to transfer to a non-hospital isolation facility. This policy provided an opportunistic insight into the low-risk COVID-19 cohort.

Our hospital registry of 554 in-hospital COVID-19 patients, recruited between 23 rd January to 30 th April 2020, were admitted to a tertiary healthcare institution for risk assessment prior to down-triaging to a non-hospital isolation facility. They were allocated into 3 groups based on the CHA(2)DS(2)-VASc scores (CV≤1; CV2-3; CV≥4). Primary outcomes were intensive care unit (ICU) admissions, mechanical ventilation, all-cause mortality and a composite end-point. The composite end-point was defined as the presence of one of the following: ICU admissions, mortality, mechanical ventilation, or any COVID-related organ involvement (pneumonia, acute respiratory distress syndrome (ARDS), acute kidney injury, pulmonary embolism, coagulopathy, acute myocardial infarction, heart failure, stroke).

The baseline characteristics of our study population differed from the Ruocco et al. study (5) . Our cohort had lower median age of 34 [28-43] years compared to the previous study (65 [53-76] years). Our median CHA(2)DS(2)-VASc score of 0 was also lower (2 [1] [2] [3] in the cited study) (5) . Seventy-six study participants (13.7%) remained asymptomatic. There was lower prevalence of comorbidities in our cohort compared to the cited study (hypertension 12.3% vs 48.6%, diabetes 5.1% vs 15.7%, ischemic heart disease 1.2% vs 11.2%, stroke 0.5% vs 7.6%, and heart failure 0.7% vs 6.1%, respectively) (5). Chronic medication use was less in our study cohort. In terms of study outcomes, there were 2 deaths in our low-risk group, both of whom were in the CV≤1 group. There were 19 (3.4%) patients requiring ICU admission, 16 (2.9%) requiring mechanical ventilation, and 59 (10.6%) with the composite end-point. We observed significant increases in ICU admissions (CV≤1: 2.8%, CV2-3: 11.1%, CV≥4: 50.0%, p<0.001), mechanical ventilation (CV≤1: 2.3%, CV2-3: 11.1%, CV≥4: 50.0%, p<0.001) and composite end-point (CV≤1: 9.8%, CV2-3: 16.7%, CV≥4: 100.0%, p<0.001) across the groups ( To date, a clinically simple risk stratification score for COVID-19 patients is lacking. Ruocco et al. has called for an urgent need to characterize these patients to identify the at-risk patients of ARDS (5). Our findings reinforce CHA(2)DS(2)-VASc score as a potential tool to identify at-risk COVID-19 individuals in a generally young, low-risk, asymptomatic or mildly symptomatic cohort. The study demonstrated that CV2-3 and CV≥4 groups displayed higher rates of mechanical ventilation, ICU admissions and composite end-point, compared to the CV≤1 group. However, we did not see a trend for all-cause mortality due to the low-risk nature of the cohort with its overall mortality rate of 0.5%.

The CHA(2)DS(2)-VASc score is indeed a simple and widely-available stratification tool that can be used in the outpatient setting or upon admission, as it is not restricted by laboratory measurements that is required in other proposed risk scores (7) . This is important as it allows clinicians to identify those who are at higher risk in the community, and may benefit from closer in-hospital monitoring. Figure   Figure 1 . Receiver Operating Characteristic curves for mechanical ventilation, intensive care unit admission, and study composite end-point for the predictor of CHA(2)DS(2)-VASc score.

Composite end-point was defined as the presence of one of the following: ICU admissions, mortality, requiring mechanical ventilation, or one of the COVID-related organ involvement (pneumonia, acute respiratory distress syndrome, acute kidney injury, pulmonary embolism, coagulopathy, acute myocardial infarction, ventricular tachycardia, myocardial injury or myocarditis, heart failure and stroke). 

Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China

Pulmonary and cardiac pathology in african American patients with COVID-19: an autopsy series from New Orleans

Coronavirus-induced myocarditis: A meta-summary of cases

Effect of coronavirus infection on the human heart: A scoping review

Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized

Demographic shift in COVID-19 patients in Singapore from an aged, at-risk population to young, migrant workers with reduced risk of severe disease

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia